Linear Clinical Research

Running trials

• Recruiting

  Evaluation of XYA02 in Patients With Advanced Solid Tumors

  NCT07670312· Phase 1/2· Source

• Recruiting

  A Phase 1a/1b, First-Time-in-Human Study of CT-202, a Nectin-4 Directed Bispecific Antibody, in Participants With Recurring Triple Negative Breast, Colorectal, Urothelial Cancers

  NCT07545122· Phase 1· Source

• Recruiting

  TLN-499 in Combination With Venetoclax in Patients With Relapsed/Refractory Solid Tumors

  NCT07713732· Phase 1· Source

• Recruiting

  A Study of ARC-02 in B-cell NHL

  NCT07691606· Phase 1· Source

• Recruiting

  A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )

  NCT07101328· Phase 1· Source

• Recruiting

  Study of INCA036978 in Participants With Myeloproliferative Neoplasms

  NCT07441694· Phase 1· Source

• Recruiting

  Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma

  NCT07249905· Phase 1/2· Source

• Recruiting

  A Single Ascending Dose and Multiple Ascending Doses Study of SYH2082 Injection in Healthy Participants

  NCT07532655· Phase 1· Source

• Recruiting

  Inhaled RB042 in Healthy Adult Volunteers, Healthy Adult Smokers and Patients With Chronic Obstructive Pulmonary Disease

  NCT07285122· Phase 1· Source

• Recruiting

  Study of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

  NCT07435038· Phase 1/2· Source

• Recruiting

  Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors

  NCT07334119· Phase 1· Source

• Recruiting

  A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRC

  NCT07244705· Phase 1/2· Source

• Recruiting

  A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms

  NCT07008118· Phase 1· Source

• Recruiting

  A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

  NCT06973187· Phase 3· Source

• Recruiting

  OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events

  NCT07136012· Phase 3· Source

• Active, not recruiting

  Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

  NCT07037433· Phase 3· Source

• Recruiting

  A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases

  NCT06570798· Phase 2· Source

• Active, not recruiting

  A Trial of HRS-5041-103 to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-5041 in Subjects With Metastatic Castration-resistant Prostate Cancer

  NCT06830850· Phase 1· Source

• Recruiting

  A Study of BBT002 in Healthy Volunteers (HVs) and in Adult Patients With Chronic Obstructive Pulmonary Disease (COPD) or Chronic Rhiosininusitis With Nasal Polyps (CRSwNP)

  NCT06944925· Phase 1· Source

• Recruiting

  A Study of Intravenous CPTX2309 in Healthy Participants and Participants With Moderate to Severe Rheumatoid Arthritis (RA) or Systemic Lupus Erythematosus (SLE)

  NCT06917742· Phase 1· Source

• Recruiting

  BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer

  NCT06756932· Phase 1· Source

• Recruiting

  A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors

  NCT06789172· Phase 1· Source

• Recruiting

  A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.

  NCT06697184· Phase 1/2· Source

• Enrolling by invitation

  A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring

  NCT06788509· Phase 1· Source

• Active, not recruiting

  A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma

  NCT06679985· Phase 2· Source

• Recruiting

  ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours

  NCT06597721· Phase 1· Source

• Recruiting

  CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.

  NCT06690775· Phase 2· Source

• Recruiting

  Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

  NCT06561048· Phase 3· Source

• Recruiting

  A Study of MT-303 in Adults With Advanced or Metastatic GPC3-Expressing Cancers, Including HCC

  NCT06478693· Phase 1· Source

• Recruiting

  A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

  NCT06465069· Phase 1· Source

• Recruiting

  IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)

  NCT06112314· Phase 3· Source

• Recruiting

  Dose Escalation and Expansion Study to Evaluate the Safety, PK, PD and Efficacy of ZE46-0134 in Adults With FLT3 Mutated or Spliceosome Mutated Relapsed or Refractory Acute Myeloid Leukemia

  NCT06366789· Phase 1· Source

• Recruiting

  Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer

  NCT06343402· Phase 1· Source

• Active, not recruiting

  Safety, Tolerability, PK and PD of ADX-850 in Participants With Hypertension

  NCT06205628· Phase 1· Source

• Recruiting

  A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors

  NCT06244771· Phase 1/2· Source

• Recruiting

  A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers

  NCT05910827· Phase 1/2· Source

• Recruiting

  Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

  NCT06162221· Phase 1/2· Source

• Recruiting

  A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

  NCT06179160· Phase 1· Source

• Recruiting

  Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)

  NCT05862012· Phase 1· Source

• Recruiting

  IKS014 in Advanced Solid Tumors That Express HER2

  NCT05872295· Phase 1· Source

• Active, not recruiting

  Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation

  NCT05919537· Phase 1· Source

• Recruiting

  IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas

  NCT05365659· Phase 1· Source

• Active, not recruiting

  A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations

  NCT05907304· Phase 1· Source

• Recruiting

  Study of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors

  NCT05969041· Phase 1· Source

• Active, not recruiting

  Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT)

  NCT05878184· Phase 1· Source

• Active, not recruiting

  ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer

  NCT05650879· Phase 1· Source

• Active, not recruiting

  Study to Assess SLN124 in Patients With Polycythemia Vera

  NCT05499013· Phase 1/2· Source

• Active, not recruiting

  Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations

  NCT05544552· Phase 1/2· Source

• Active, not recruiting

  A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors

  NCT05581004· Phase 1· Source

• Recruiting

  Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)

  NCT05519449· Phase 1· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer14 recruiting
• Colorectal cancer9 recruiting
• Follicular lymphoma5 recruiting
• Gastric and esophageal cancer5 recruiting
• Head and neck cancer5 recruiting
• Mantle cell lymphoma5 recruiting
• Ovarian cancer5 recruiting
• Pancreatic cancer5 recruiting
• Chronic lymphocytic leukaemia4 recruiting
• Diffuse large B-cell lymphoma4 recruiting
• Myeloproliferative neoplasms4 recruiting
• Prostate cancer4 recruiting
• Triple-negative breast cancer4 recruiting
• Acute myeloid leukemia3 recruiting
• Liver and biliary tract cancer3 recruiting
• Myelodysplastic syndromes3 recruiting
• Bladder cancer2 recruiting
• Cervical cancer2 recruiting
• COPD2 recruiting
• Endometrial cancer2 recruiting
• Hodgkin lymphoma2 recruiting
• Lupus (SLE)2 recruiting
• Melanoma2 recruiting
• Mesothelioma2 recruiting
• Rheumatoid arthritis2 recruiting
• Sarcoma2 recruiting
• Asthma1 recruiting
• Childhood cancers1 recruiting
• Chronic myeloid leukaemia1 recruiting
• Coronary artery disease1 recruiting
• Metastatic breast cancer1 recruiting
• Multiple myeloma1 recruiting
• Neuroendocrine tumours1 recruiting
• Obesity1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  A Trial of HRS-1893 in Healthy Volunteers

  NCT07033455· Early phase 1· Source

• Recruiting

  A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Atopic Dermatitis (AD)

  NCT06808477· Phase 1· Source

• Terminated

  A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification

  NCT06585488· Phase 1· Source

• Completed

  A Study of TeriQ Patch in Healthy Adult Female Participants

  NCT06644040· Phase 1· Source

• Completed

  Сlinical Study Aiming to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses of ZE63-0302 in Healthy Volunteers

  NCT06780124· Phase 1· Source

• Completed

  A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Help People With Excess Body Weight Lose Weight

  NCT06326060· Phase 2· Source

• Completed

  A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies

  NCT05665530· Phase 1· Source

• Terminated

  A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies

  NCT05828589· Phase 1· Source

• Completed

  Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy

  NCT05583552· Phase 2· Source

• Terminated

  NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors

  NCT05252390· Phase 1· Source

• Completed

  A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

  NCT04657224· Phase 1· Source

• Completed

  A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors

  NCT04670679· Phase 1· Source

• Completed

  A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

  NCT04540796· Phase 1· Source

• Terminated

  Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors

  NCT04383210· Phase 2· Source

• Completed

  Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors

  NCT04242199· Phase 1· Source

• Completed

  REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors

  NCT04526106· Phase 1/2· Source

• Completed

  IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma

  NCT04109456· Phase 1· Source

• Completed

  Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors

  NCT04215978· Phase 1· Source

• Completed

  To Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of ABN401 in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer Harboring c-MET Dysregulation

  NCT04052971· Phase 1· Source

• Completed

  A Study of JNJ-67856633 in Participants With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

  NCT03900598· Phase 1· Source

• Completed

  A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL

  NCT03740529· Phase 1/2· Source

• Completed

  A Phase II Study to Determine Pembrolizumab as Frontline Treatment of Patients With Hodgkin Lymphoma

  NCT03331731· Phase 2· Source

• Completed

  Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab

  NCT03674567· Phase 1/2· Source

Trial sites

• Linear Clinical Research1 trial
• Linear Clinical Research46 trials
• Linear Clinical Research Limited7 trials
• Linear Clinical Research Ltd15 trials
• Linear Clinical Research14 trials
• Linear Clinical Research Limited1 trial
• Linear Clinical Research, LTD5 trials

Conditions

Diseases this institution publishes on or runs trials for.

• Mantle cell lymphoma4 works · 9 trials